Warner Pharmaceutical (688799.SH) announced on October 17th that it has received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration regarding the change of the pharmaceutical license holder for the sale of the pharmaceutical solution for inhalation of terbutaline sulfate. The inhalation solution of terbutaline sulfate is used to relieve bronchospasm associated with asthma, chronic bronchitis, emphysema, and other lung diseases.
华纳药厂(688799.SH)：硫酸特布他林雾化吸入用溶液获得药品补充申请批准通知书
Warner Pharmaceuticals (688799.SH): The pharmaceutical supplementary application approval notice for the aerosol inhalation solution of terbutaline sulfate has been obtained.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated